Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA safety study in children and adolescents with brain tumors
NL-OMON52327Phase 2Not yet recruiting
- Sponsor
- Universität Münster
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in brain neoplasm, sponsored by Universität Münster. Primary endpoint: Severe adverse event incidence. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on NL-OMON52327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52327.